Quantcast

Latest Monoclonal antibodies Stories

2014-03-05 04:22:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific ) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" [http://www.researchandmarkets.com/research/885sfr/bispecific ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Antibody based therapeutics are the fastest growing segment of the drugs and...

Food Allergy Oral Immunotherapy More Effective When Paired With Asthma Drug Omalizumab
2014-03-01 04:56:07

Brett Smith for redOrbit.com - Your Universe Online New research from Stanford University and Johns Hopkins Medical School has shown that an asthma drug can be used to help desensitize people to several food allergens all at once, according to a new report in the journal Allergy, Asthma & Clinical Immunology. The new findings expand on previous research from the same team that showed a technique called oral immunotherapy could be used to desensitize someone to multiple food...

2014-02-25 23:36:32

Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody mixtures for the treatment of cancer. St. Louis, Missouri (PRWEB) February 25, 2014 Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S...

2014-02-25 20:22:13

PASADENA, Calif., Feb. 25, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates using its proprietary monoclonal antibody (mAb) technology platform, today announced the issuance of its first patent, U.S. Patent No. 8,658,774, entitled "Novel Meditopes and Related Meditope-Monoclonal Antibody Delivery Systems, Synthesis and Therapeutic Uses Thereof." "We view the issuance of this patent, about two years from initial filing,...

2014-02-24 23:03:30

Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. Houston, TX (PRWEB) February 24, 2014 Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. The research, funded by Novartis Pharmaceuticals, appeared in Current Medical Research and Opinion this month. It concerns a novel liquid formulation of the monoclonal antibody omalizumab...

2014-02-21 08:26:00

DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as monoclonal antibodies market forecasts in breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and...

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-02-19 08:31:36

- BioMotiv Establishes Kodosil Bio to Develop Collaboration Compounds - SAN DIEGO and CLEVELAND, Feb. 19, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound...

2014-02-19 08:31:28

Proceeds Bring Series B to CHF 44.9 Million ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million. The additional financing will primarily...

2014-02-17 23:02:51

Biosimilars Products Market report is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html) (PRWEB) February 17, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) -...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related